25 terminated. 25 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Terminated 25 |
| Phase 2 | 7 | Terminated 7 |
Follow Carcinogenesis: new trials by email Literature Review of Carcinogenesis trials Research Report on Carcinogenesis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg - Myeloproliferative Neoplasm | Phase 1 | Terminated | Joseph Jurcic | 2 | 2022-01-28 | 2024-04-23 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Terminated | M.D. Anderson Cancer Center | 15 | 2019-01-31 | 2026-11-04 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia Axitinib, Bosutinib, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML) | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2017-03-20 | 2020-11-19 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil - Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome | Phase 1 | Terminated | Stanford University | 1 | 2016-02-01 | 2018-09-12 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Adavosertib, Belinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 2015-08-18 | 2026-01-30 |
| An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) MEK-162, Nilotinib, Questionnaires - Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2015-03-11 | 2020-02-12 |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML metformin hydrochloride, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Northwestern University | 2 | 2015-03-11 | 2019-01-31 |
| An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Dasatinib, Decitabine - Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 32 | 2012-06-12 | 2020-10-22 |
| Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Dasatinib, laboratory biomarker analysis - Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 5 | 2012-05-01 | 2020-12-17 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia entinostat, sorafenib tosylate, pharmacological study - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 44 | 2010-06-01 | 2013-09-19 |
| Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation Irradiated haploidentical allogeneic lymphocytes, total-body irradiation - Leukemia, Lymphoma | Phase 1 | Terminated | University of Medicine and Dentistry of New Jersey | 4 | 2009-10-01 | 2013-09-17 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| A Study for Patients With Acute Leukemia LY2523355 - Acute Leukemia | Phase 1 | Terminated | Eli Lilly and Company | 33 | 2008-06-01 | 2019-05-13 |
| Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer alemtuzumab, busulfan, cyclophosphamide - Graft Versus Host Disease, Leukemia | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2007-09-01 | 2017-05-24 |
| Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer busulfan, etoposide, intensity-modulated radiation therapy - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 / Phase 2 | Terminated | City of Hope Medical Center | 25 | 2007-06-11 | 2023-11-30 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia SJG-136 - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Terminated | National Cancer Institute (NCI) | 25 | 2005-12-01 | 2013-09-30 |
| Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12 - Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 4 | 2005-07-01 | 2017-11-29 |
Showing 20 of 25. Sign in to see all of them.
Blast Crisis (25) · Leukemia, Myeloid, Acute (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Congenital Abnormalities (10) · Leukemia, Myeloid, Chronic-Phase (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Leukemia, Myeloid, Accelerated Phase (8) · Myelodysplastic Syndromes (8) · Leukemia (7) · Lymphoma, Non-Hodgkin (6) · Burkitt Lymphoma (5) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Large B-Cell, Diffuse (5) · Anemia, Refractory, with Excess of Blasts (4)
Bone Marrow Diseases (25) · Cell Transformation, Neoplastic (25) · Chronic Disease (25) · Disease Attributes (25) · Hematologic Diseases (25) · Hemic and Lymphatic Diseases (25) · Neoplasms (25) · Neoplasms by Histologic Type (25) · Neoplastic Processes (25) · Pathologic Processes (25) · Pathological Conditions, Signs and Symptoms (25) · Leukemia, Myeloid (24) · Myeloproliferative Disorders (22) · Leukemia (18)
Dasatinib (3) · Sirolimus (3) · Busulfan (2) · Cytarabine (2) · Decitabine (2) · Doxorubicin (2) · Imatinib Mesylate (2) · Peripheral Blood Stem Cell Transplantation (2) · Sorafenib (2) · Tretinoin (2) · ponatinib (2) · venetoclax (2) · 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1)
M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (6) · Fred Hutchinson Cancer Center (2) · Masonic Cancer Center, University of Minnesota (2) · Barbara Ann Karmanos Cancer Institute (1) · City of Hope Medical Center (1) · Eli Lilly and Company (1) · Joseph Jurcic (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Stanford University (1) · University of Medicine and Dentistry of New Jersey (1) · Washington University School of Medicine (1)
United States (24) · Canada (1)
Farhad Ravandi-Kashani (2) · Tapan M Kadia (2) · Abhinav Deol, M.D. (1) · Alex Adjei (1) · Ann E. Woolfrey, MD (1) · Anthony Stein (1) · Danielle A Shafer (1) · Gunnar Ragnarsson (1) · Jessica Altman, MD (1) · John E. Wagner, MD (1) · Jorge Cortes, MD (1) · Joseph Jurcic, MD (1) · Lara Davis, MD (1) · Linda J. Burns, MD (1)
PMID 19139736, PMID 20460644, PMID 23393050, PMID 39863139
N01CM00100 (1), P01CA018029 (1), P30CA015704 (1), P30CA072720 (1), P50CA100632 (1), R21CA112936 (1), U01CA062461 (1), U01CA076576 (1), U01CA097452 (1), UM1CA186644 (1), UM1CA186716 (1)